<DOC>
	<DOCNO>NCT01386853</DOCNO>
	<brief_summary>This 12-week , randomize , multicenter , double-blind , active-controlled , non-inferiority study ( TATPITA20101005 ) compare efficacy safety pitavastatin ( Livalo® ) atorvastatin ( Lipitor® ) high risk hypercholesterolemic patient .</brief_summary>
	<brief_title>Efficacy Safety Study Pitavastatin Atorvastatin High Risk Hypercholesterolemic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Patient age ≥ 20 year old &lt; 75 year old . Patient eligible able participate study accepts enter study signing write informed consent . Patient fast LDLC &gt; 100 mg/dL . The concentration LDLC obtain laboratory examination . Patient least one follow description ( NCEP ATP III guideline ) . Female patient childbearing potential must take reliable contraception method ( ) participation study . Patient participate investigational study within 3 month . Patient take medication natural health food know alter blood lipid profile within 4 week . Patient take medication food prohibit study . Patient take Amiodarone exclude study ( due long half life medication ) . Patient diagnose type 1 DM use insulin/insulin analog medication . Patient history multiple drug allergy know allergy HMGCoA reductase inhibitor . Patient TG &gt; 400 mg/dL . Excessive obesity define BMI 35 kg/m2 . Cerebral vascular disease ( include cerebrovascular hemorrhage ischemia , transient ischemic attack ) diagnose within 3 month . Myocardial infarction , heart failure ( NYHA class III IV ) , gross cardiac enlargement ( cardiothoracic ratio &gt; 0.5 ) , significant heart block cardiac arrhythmia within 3 month ; history uncontrolled complex ventricular arrhythmia , uncontrolled atrial fibrillation/flutter uncontrolled supraventricular tachycardia , pacemaker implantable cardiac device eligible study . Patient advance renal disorder ( Serum creatinine level ≥ 2 mg/dL BUN ≥ 25 mg/dL ) . Patient advance hepatic disorder ( AST ALT level ≥ 100 IU/L ) Patient CK level &gt; 5 × ULRR time point Visit 1 Visit 2 . Patient poorly control diabetes mellitus ( HbA1c &gt; 9.0 % ) patient severe hypertension ( &gt; 180 mmHg systolic &gt; 120 mmHg diastolic blood pressure ) . Patient hypothyroidism , hereditary muscular disorder , family history history druginduced myopathy . Patient significant alcohol consumption ( &gt; 65 mL pure alcohol ) within 48 hour Visit 2 . Any major surgery within 3 month prior Visit 2 . Female patient lactating , pregnant plan become pregnant . Patient condition judge investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Pitavastatin</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>